CA2595699A1 - Compositions, kits and methods for identification, assessment, prevention and therapy of cancer - Google Patents

Compositions, kits and methods for identification, assessment, prevention and therapy of cancer Download PDF

Info

Publication number
CA2595699A1
CA2595699A1 CA002595699A CA2595699A CA2595699A1 CA 2595699 A1 CA2595699 A1 CA 2595699A1 CA 002595699 A CA002595699 A CA 002595699A CA 2595699 A CA2595699 A CA 2595699A CA 2595699 A1 CA2595699 A1 CA 2595699A1
Authority
CA
Canada
Prior art keywords
marker
cancer
subject
sample
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002595699A
Other languages
English (en)
French (fr)
Inventor
Ronald Depinho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2595699A1 publication Critical patent/CA2595699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002595699A 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer Abandoned CA2595699A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65422705P 2005-02-17 2005-02-17
US60/654,227 2005-02-17
US69006405P 2005-06-13 2005-06-13
US60/690,064 2005-06-13
PCT/US2006/005584 WO2006089087A2 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Publications (1)

Publication Number Publication Date
CA2595699A1 true CA2595699A1 (en) 2006-08-24

Family

ID=36917075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002595699A Abandoned CA2595699A1 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Country Status (5)

Country Link
US (1) US8168602B2 (enExample)
EP (1) EP1855727A2 (enExample)
JP (1) JP2008536480A (enExample)
CA (1) CA2595699A1 (enExample)
WO (1) WO2006089087A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008016996A2 (en) * 2006-08-01 2008-02-07 Joslin Diabetes Center, Inc. Methods of modulating metabolic memory
EP2061906B1 (en) * 2006-09-12 2011-08-31 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
CA2688536A1 (en) * 2007-05-21 2008-11-27 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
JP2011001267A (ja) * 2007-10-17 2011-01-06 Univ Of Tokyo 大腸癌治療薬
JP5586164B2 (ja) * 2009-04-06 2014-09-10 聡明 渡邉 潰瘍性大腸炎患者の癌化リスクを決定する方法
WO2010121370A1 (en) * 2009-04-20 2010-10-28 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
JP6114035B2 (ja) * 2010-02-10 2017-04-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肺癌検出用唾液バイオマーカー
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
US8709718B1 (en) 2011-02-12 2014-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method of treating lung cancer
WO2013066641A1 (en) * 2011-10-21 2013-05-10 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
EP4361606A3 (en) * 2012-02-03 2024-07-10 California Institute of Technology Signal encoding and decoding in multiplexed biochemical assays
JP6384930B2 (ja) * 2014-03-25 2018-09-05 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ がん遺伝子変異の機能確認におけるｒｎａ解析のためのシステムおよび方法
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
WO2017127537A1 (en) * 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
EP3203413A1 (en) * 2016-02-08 2017-08-09 Ecole Polytechnique Federale De Lausanne (Epfl) Method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof
KR20250047324A (ko) 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
CN109125729A (zh) * 2018-09-06 2019-01-04 苏州吉玛基因股份有限公司 与非小细胞肺癌诊疗相关的基因BRD9及其siRNAs和应用
JP7262736B2 (ja) * 2018-10-31 2023-04-24 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
US20220280544A1 (en) * 2019-07-24 2022-09-08 Tohoku University Chimeric molecule, pharmaceutical composition, method for cleaving target nucleic acid, and kit for target nucleic acid cleavage or diagnosis
CN110317876A (zh) * 2019-08-02 2019-10-11 苏州宏元生物科技有限公司 一组染色体不稳定变异在制备诊断多发性骨髓瘤、评估预后的试剂或试剂盒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
JP2008512984A (ja) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法

Also Published As

Publication number Publication date
EP1855727A2 (en) 2007-11-21
US8168602B2 (en) 2012-05-01
US20090297525A1 (en) 2009-12-03
JP2008536480A (ja) 2008-09-11
WO2006089087A2 (en) 2006-08-24
WO2006089087A9 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US9309564B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8168602B2 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
US7705120B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
Manne et al. Development and progression of colorectal neoplasia
WO2010045470A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20080242742A1 (en) Animal models of pancreatic adenocarcinoma and uses therefor
US20100298158A1 (en) Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer
EP2531858B1 (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
WO2004106495A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US8999633B2 (en) Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
JP2012504426A (ja) Ｇｏｌｐｈ３を使用する癌の診断、予後およびモニタリングのための組成物、キットおよび方法
JP4272512B2 (ja) 癌
Hosoi et al. Suppression of anchorage-independent growth by expression of the ataxia-telangiectasia group D complementing gene, ATDC
Fong et al. Molecular basis of lung carcinogenesis
WO2022207760A1 (en) Genomic predictor of outcome in cancer
Cui et al. Identification of differentially expressed genes associated with papillary thyroid carcinoma
US20140079698A1 (en) Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
Shames et al. The Molecular Genetics of Lung Cancer
Gutierrez et al. Molecular Genetics and Cytogenetics in Cancer
Grundy The molecular genetics of wilms tumour and the wilms tumour predisposition syndromes

Legal Events

Date Code Title Description
FZDE Discontinued